In view of the possible involvement of the APN paradox in linking neurodegeneration to metabolic disease, this may account for the pathological positioning of T2DM upstream of AD in aging, suggesting that therapeutic targeting of APN might be a viable strategy. The gene discussed is ANPEP; the disease is metabolic disease.